Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06634420 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06634420 · ClinicalTrials.gov record · last posted 2026-07-29

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Name: HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — clinical trial record (NCT06634420)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorIntellia Therapeutics

Started2025-01-15

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Amendment record 16 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 16 times since 2024-10-08; most recent amendment 2026-05-14. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-06-09

Status change Recruiting→Active, Not Recruitingv13

Trial Details

NCT Number	NCT06634420
Lead Sponsor	Intellia Therapeutics
Conditions	Hereditary Angioedema
Enrollment	80 participants
Start Date	2025-01-15
Primary Completion	2026-02-10 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-29